RAF1 and thyroiditis: The potential enthusiasm that targeting the linear RAS–RAF–MEK–ERK cascade in patients with thyroid with different oncogenic alterations must be reconciled with the recent data of Solit et al (2006) who examined the response of a series of melanoma cell lines to MEK1/2 inhibitors in vitro.